Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 11/20 | 0.35 |
| ▸ | JAK2 | O60674 | 9/20 | 0.35 |
| ▸ | JAK3 | P52333 | 9/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5358384 | 0.81 | SMN1; SMN2 (0.37) | SMN1; SMN2 | |
| SCHEMBL5355388 | 0.80 | HPGDS (0.33) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL2585149 | 0.75 | SMN1; SMN2 (0.53) | SMN1; SMN2HSD17B10JAK1JAK2JAK3 | |
| Hydrochloric Acid SCHEMBL15826105 | 0.73 | SMN1; SMN2 (0.52) | SMN1; SMN2HSD17B10JAK1JAK2JAK3 | |
| SCHEMBL5070059 | 0.73 | HSD17B10 (0.42) | SMN1; SMN2HSD17B10JAK1JAK2JAK3 | |
| SCHEMBL5359018 | 0.71 | — | — | |
| SCHEMBL16480146 | 0.71 | SMN1; SMN2 (0.50) | SMN1; SMN2HSD17B10JAK1JAK2JAK3 | |
| SCHEMBL15200303 | 0.71 | SMN1; SMN2 (0.50) | SMN1; SMN2HSD17B10JAK1JAK2JAK3 | |
| SCHEMBL5355384 | 0.69 | — | — | |
| SCHEMBL14808770 | 0.69 | SMN1; SMN2 (0.66) | SMN1; SMN2HSD17B10JAK1JAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1831158-A1 | NOVEL CYCLOHEXANE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-09-12 | — | — | EP | disclosed |
| US-7253282-B2 | Hexafluoroisopropanol substituted cyclohexane derivatives | HOFFMAN-LA ROCHE INC. (US) | 2007-08-07 | — | — | US | disclosed |
| WO-2006066779-A1 | NOVEL CYCLOHEXANE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-06-29 | — | — | WO | disclosed |
| US-20060135601-A1 | Novel hexafluoroisopropanol substituted cyclohexane derivatives | HOFFMANN-LA ROCHE INC. | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135601-A1 | Novel hexafluoroisopropanol substituted cyclohexane derivatives | NR1H3, NR1H2, NR1I2 | SMN1; SMN2 4559/4885HSD17B10 667/4885JAK1 4508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.